Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C.

López-Rodríguez R, Hernández-Bartolomé Á, Borque MJ, Rodríguez-Muñoz Y, Martín-Vílchez S, García-Buey L, González-Moreno L, Real-Martínez Y, Muñoz de Rueda P, Salmerón J, Vidal-Castiñeira JR, López-Larrea C, Rodrigo L, Moreno-Otero R, Sanz-Cameno P.

PLoS One. 2017 Jul 12;12(7):e0180927. doi: 10.1371/journal.pone.0180927. eCollection 2017.

2.

Intrahepatic angiopoietin-2 correlates with chronic hepatitis C progression and is induced in hepatitis C virus replicon systems.

Hernández-Bartolomé Á, López-Rodríguez R, García-Buey L, Martín-Vílchez S, Rodríguez-Muñoz Y, Borque MJ, González-Moreno L, Real-Martínez Y, Mendoza-Ridruejo J, Martín-Pérez E, Moreno-Otero R, Sanz-Cameno P.

Liver Int. 2017 Aug;37(8):1148-1156. doi: 10.1111/liv.13352. Epub 2017 Feb 6.

PMID:
28027429
3.

Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C.

Hernández-Bartolomé Á, López-Rodríguez R, Borque MJ, González-Moreno L, Real-Martínez Y, García-Buey L, Moreno-Otero R, Sanz-Cameno P.

World J Gastroenterol. 2016 Nov 28;22(44):9744-9751.

4.

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.

van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D'Ambrosio R, Pol S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HLA.

J Hepatol. 2017 Mar;66(3):485-493. doi: 10.1016/j.jhep.2016.10.017. Epub 2016 Oct 22.

PMID:
27780714
5.

Correction for Quer at al., High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods.

Quer J, Gregori J, Rodríguez-Frias F, Buti M, Madejon A, Perez-Del-Pulgar S, Garcia-Cehic D, Casillas R, Blasi M, Homs M, Tabernero D, Alvarez-Tejado M, Muñoz JM, Cubero M, Caballero A, delCampo JA, Domingo E, Belmonte I, Nieto L, Lens S, Muñoz-de-Rueda P, Sanz-Cameno P, Sauleda S, Bes M, Gomez J, Briones C, Perales C, Sheldon J, Castells L, Viladomiu L, Salmeron J, Ruiz-Extremera A, Quiles-Pérez R, Moreno-Otero R, López-Rodríguez R, Allende H, Romero-Gómez M, Guardia J, Esteban R, Garcia-Samaniego J, Forns X, Esteban JI.

J Clin Microbiol. 2016 Jul;54(7):1933. doi: 10.1128/JCM.01007-16. No abstract available.

6.

Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection.

Ampuero J, del Campo JA, Rojas L, García-Lozano RJ, Buti M, Solá R, Forns X, Moreno-Otero R, Andrade R, Diago M, Salmerón J, Rodrigo L, Pons JA, Navarro JM, Calleja JL, García-Samaniego J, García-Valdecasas M, Rojas Á, Millán R, González-Escribano MF, Romero-Gómez M.

Genes Immun. 2015 Jul-Aug;16(5):297-300. doi: 10.1038/gene.2015.14. Epub 2015 Apr 30.

PMID:
25928882
7.

High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods.

Quer J, Gregori J, Rodríguez-Frias F, Buti M, Madejon A, Perez-del-Pulgar S, Garcia-Cehic D, Casillas R, Blasi M, Homs M, Tabernero D, Alvarez-Tejado M, Muñoz JM, Cubero M, Caballero A, del Campo JA, Domingo E, Belmonte I, Nieto L, Lens S, Muñoz-de-Rueda P, Sanz-Cameno P, Sauleda S, Bes M, Gomez J, Briones C, Perales C, Sheldon J, Castells L, Viladomiu L, Salmeron J, Ruiz-Extremera A, Quiles-Pérez R, Moreno-Otero R, López-Rodríguez R, Allende H, Romero-Gómez M, Guardia J, Esteban R, Garcia-Samaniego J, Forns X, Esteban JI.

J Clin Microbiol. 2015 Jan;53(1):219-26. doi: 10.1128/JCM.02093-14. Epub 2014 Nov 5. Erratum in: J Clin Microbiol. 2016 Jul;54(7):1933.

8.

Inhibition of tyrosine kinase receptor Tie2 reverts HCV-induced hepatic stellate cell activation.

Martín-Vílchez S, Rodríguez-Muñoz Y, López-Rodríguez R, Hernández-Bartolomé, Borque-Iñurrita MJ, Molina-Jiménez F, García-Buey L, Moreno-Otero R, Sanz-Cameno P.

PLoS One. 2014 Oct 10;9(10):e106958. doi: 10.1371/journal.pone.0106958. eCollection 2014.

9.

Abulcasis, the father of modern surgery.

Moreno-Otero R.

Med Arch. 2013;67(2):151. No abstract available.

PMID:
24341068
10.

Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease.

Martín-Domínguez V, González-Casas R, Mendoza-Jiménez-Ridruejo J, García-Buey L, Moreno-Otero R.

Rev Esp Enferm Dig. 2013 Aug;105(7):409-20.

11.

Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link.

Hernández-Bartolomé A, López-Rodríguez R, Rodríguez-Muñoz Y, Martín-Vílchez S, Borque MJ, García-Buey L, González-Moreno L, Real Y, Moreno-Otero R, Sanz-Cameno P.

PLoS One. 2013 Jun 18;8(6):e66143. doi: 10.1371/journal.pone.0066143. Print 2013.

12.

Letter: impact of mild alcohol consumption in chronic hepatitis C treatment.

Trapero-Marugán M, Moreno-Otero R.

Aliment Pharmacol Ther. 2013 Jun;37(11):1118-9. doi: 10.1111/apt.12321. No abstract available.

13.

Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy.

López-Rodríguez R, Hernández-Bartolomé Á, Borque MJ, Rodríguez-Muñoz Y, Martín-Vílchez S, Trapero-Marugán M, García-Buey L, Muñoz de Rueda P, Rodrigo L, Vidal-Castiñeira JR, Salmerón J, Moreno-Otero R, Sanz-Cameno P.

Genes Immun. 2013 Jul-Aug;14(5):317-24. doi: 10.1038/gene.2013.24. Epub 2013 Apr 25.

PMID:
23615070
14.

[Hepatitis B vaccine-induced liver injury].

Solano-Iturri G, García-Buey ML, Blanco-Sampascual S, Moreno-Otero R.

Med Clin (Barc). 2013 Dec 7;141(11):510-1. doi: 10.1016/j.medcli.2013.02.033. Epub 2013 Apr 21. Spanish. No abstract available.

PMID:
23611823
15.

Liver biopsy in the management of autoimmune hepatitis acute severe onset.

Moreno-Otero R.

Dig Dis Sci. 2013 Jun;58(6):1808-9. doi: 10.1007/s10620-013-2662-5. Epub 2013 Apr 16. No abstract available.

PMID:
23589142
16.

May oxidative stress contribute to autoimmune hepatitis pathogenesis, and can antioxidants be of value as adjuvant therapy for refractory patients?

Moreno-Otero R.

Dig Dis Sci. 2013 May;58(5):1440-1. doi: 10.1007/s10620-013-2622-0. Epub 2013 Mar 17. No abstract available.

PMID:
23504353
17.

Preliminary evidence of sustained expression of angiopoietin-2 during monocyte differentiation in chronic hepatitis C.

Rodríguez-Muñoz Y, Martín-Vílchez S, López-Rodríguez R, Hernández-Bartolomé Á, García-Buey L, Borque MJ, Moreno-Otero R, Sanz-Cameno P.

Liver Int. 2013 Jul;33(6):864-70. doi: 10.1111/liv.12125. Epub 2013 Feb 19.

PMID:
23419030
18.

[Effects of hepatitis B virus X protein on chronic hepatitis B pathophysiology].

Martín-Vílchez S, Moreno-Otero R, Sanz-Cameno P; Grupo CIBERehd de Hepatología del Hospital Universitario de La Princesa.

Med Clin (Barc). 2013 Jun 4;140(11):508-13. doi: 10.1016/j.medcli.2012.09.012. Epub 2012 Dec 12. Review. Spanish.

PMID:
23245531
19.

Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.

Poynard T, Bruix J, Schiff ER, Diago M, Berg T, Moreno-Otero R, Lyra AC, Carrilho F, Griffel LH, Boparai N, Jiang R, Burroughs M, Brass CA, Albrecht JK.

J Hepatol. 2013 Mar;58(3):452-9. doi: 10.1016/j.jhep.2012.11.001. Epub 2012 Nov 14.

PMID:
23159770
20.

Role of percutaneous liver biopsy.

Rodziewicz M, Moreno-Otero R.

Hepat Mon. 2012 Apr;12(4):294-5. doi: 10.5812/hepatmon.854. Epub 2012 Apr 30. No abstract available.

21.

Role of tight junctions in hepatitis C virus infection.

Benedicto I, Molina-Jiménez F, García-Buey L, Gondar V, López-Cabrera M, Moreno-Otero R, Majano PL.

Rev Esp Enferm Dig. 2012 May;104(5):255-63. Review. No abstract available.

22.

Letter: acute hepatitis B - to treat or not to treat?

Casals-Seoane F, Arberas-Diez B, Moreno-Otero R.

Aliment Pharmacol Ther. 2012 Jul;36(1):76-7. doi: 10.1111/j.1365-2036.2012.05123.x. No abstract available.

23.

Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature.

Chaparro M, Trapero-Marugán M, Guijarro M, López C, Moreno-Otero R, Gisbert JP.

J Crohns Colitis. 2013 Mar;7(2):e61-5. doi: 10.1016/j.crohns.2012.04.005. Epub 2012 Apr 30. Review.

PMID:
22552273
24.

Safety of methotrexate for inflammatory bowel disease.

Moreno-Otero R, García-Buey L, Trapero-Marugán M.

Dig Liver Dis. 2012 Aug;44(8):706-7. doi: 10.1016/j.dld.2012.03.012. Epub 2012 Apr 24. No abstract available.

PMID:
22538205
25.

Commentary: ursodeoxycholic acid as chemoprevention in inflammatory bowel disease and primary sclerosing cholangitis.

Santander C, Moreno-Otero R.

Aliment Pharmacol Ther. 2012 Apr;35(7):846; discussion 847. doi: 10.1111/j.1365-2036.2012.05019.x. No abstract available.

26.

Idiopathic portal hypertension complicated by ischemic hepatitis: the diagnostic importance of hemodynamics and liver biopsy.

Miranda-García P, López-Martín MC, Alvarez-Malé T, Casanova-González MJ, Santander C, Bañares R, Moreno-Otero R, Trapero-Marugán M.

Rev Esp Enferm Dig. 2012 Feb;104(1):45-7. English, Spanish. No abstract available.

PMID:
22300122
27.

Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle.

Molina-Jimenez F, Benedicto I, Dao Thi VL, Gondar V, Lavillette D, Marin JJ, Briz O, Moreno-Otero R, Aldabe R, Baumert TF, Cosset FL, Lopez-Cabrera M, Majano PL.

Virology. 2012 Mar 30;425(1):31-9. doi: 10.1016/j.virol.2011.12.021. Epub 2012 Jan 24.

28.

Evaluation of liver fibrosis by transient elastography (Fibroscan®) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial.

Barbero-Villares A, Mendoza Jiménez-Ridruejo J, Taxonera C, López-Sanromán A, Pajares R, Bermejo F, Pérez-Calle JL, Mendoza JL, Algaba A, Moreno-Otero R, Maté J, Gisbert JP; Madrid Group for the Study of Inflammatory Bowel Disease ENICMAD.

Scand J Gastroenterol. 2012 May;47(5):575-9. doi: 10.3109/00365521.2011.647412. Epub 2012 Jan 10.

PMID:
22229701
29.

Autoimmune hepatitis after long-term methotrexate therapy for rheumatoid arthritis.

Moreno-Otero R, García-Buey L, García-Sanchez A, Trapero-Marugán M.

Curr Drug Saf. 2011 Jul;6(3):197-200.

PMID:
22122395
30.

Antioxidant agents in the prevention of hepatocellular carcinoma.

Moreno-Otero R, Trapero-Marugan M.

Eur J Cancer Prev. 2012 Jul;21(4):323-5. doi: 10.1097/CEJ.0b013e32834dbc6d. No abstract available.

PMID:
22044850
31.

Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C.

Lopez-Rodriguez R, Trapero-Marugan M, Borque MJ, Roman M, Hernandez-Bartolome A, Rodriguez-Muñoz Y, Martin-Vilchez S, Abad-Santos F, Muñoz de Rueda P, Vidal-Castiñeira JR, Rodrigo L, Salmeron J, Moreno-Otero R, Sanz-Cameno P.

Clin Pharmacol Ther. 2011 Nov;90(5):712-21. doi: 10.1038/clpt.2011.189. Epub 2011 Oct 12.

PMID:
21993426
32.

Mycophenolate mofetil for patients with autoimmune hepatitis and overlap syndromes.

García-Buey L, Moreno-Otero R.

Aliment Pharmacol Ther. 2011 Sep;34(6):682-4; author reply 684-5. doi: 10.1111/j.1365-2036.2011.04763.x. No abstract available.

33.

Peripheral blood monocyte subsets predict antiviral response in chronic hepatitis C.

Rodríguez-Muñoz Y, Martín-Vílchez S, López-Rodríguez R, Hernández-Bartolomé A, Trapero-Marugán M, Borque MJ, Moreno-Otero R, Sanz-Cameno P.

Aliment Pharmacol Ther. 2011 Oct;34(8):960-71. doi: 10.1111/j.1365-2036.2011.04807.x. Epub 2011 Aug 17.

34.

The molecular and pathophysiological implications of hepatitis B X antigen in chronic hepatitis B virus infection.

Martin-Vilchez S, Lara-Pezzi E, Trapero-Marugán M, Moreno-Otero R, Sanz-Cameno P.

Rev Med Virol. 2011 Sep;21(5):315-29. doi: 10.1002/rmv.699. Epub 2011 Jul 14. Review.

PMID:
21755567
35.

Soluble angiogenic factors in patients with acute pancreatitis.

Espinosa L, Linares PM, Bejerano A, Lopez C, Sanchez A, Moreno-Otero R, Gisbert JP.

J Clin Gastroenterol. 2011 Aug;45(7):630-7. doi: 10.1097/MCG.0b013e31820d3533.

PMID:
21750433
36.

Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry.

Benedicto I, Molina-Jiménez F, Moreno-Otero R, López-Cabrera M, Majano PL.

World J Gastroenterol. 2011 Jun 14;17(22):2683-90. doi: 10.3748/wjg.v17.i22.2683.

37.

Evaluation of liver fibrosis by transient elastography in methotrexate treated patients.

Barbero-Villares A, Mendoza J, Trapero-Marugan M, Gonzalez-Alvaro I, Daudén E, Gisbert JP, Moreno-Otero R.

Med Clin (Barc). 2011 Nov 26;137(14):637-9. doi: 10.1016/j.medcli.2010.12.024. Epub 2011 Jun 29.

PMID:
21719043
38.

Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin.

de Rueda PM, López-Nevot MÁ, Sáenz-López P, Casado J, Martín-Casares A, Palomares P, Quiles R, Gila A, Romero-Gómez M, Pavón EJ, Muñoz JA, Carazo A, Sanz-Cameno P, Moreno-Otero R, Diago M, León J, Ruiz-Extremera A, Salmerón J.

Am J Gastroenterol. 2011 Jul;106(7):1246-54. doi: 10.1038/ajg.2011.82. Epub 2011 Jun 14.

PMID:
21670772
39.

Esophageal motor abnormalities in eosinophilic esophagitis identified by high-resolution manometry.

Martín Martín L, Santander C, Lopez Martín MC, Espinoza-Ríos J, Chavarría-Herbozo C, Gisbert JP, Moreno-Otero R.

J Gastroenterol Hepatol. 2011 Sep;26(9):1447-50. doi: 10.1111/j.1440-1746.2011.06770.x.

PMID:
21575059
40.

Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.

Trapero-Marugán M, Mendoza J, Chaparro M, González-Moreno L, Moreno-Monteagudo JA, Borque MJ, Moreno-Otero R.

World J Gastroenterol. 2011 Jan 28;17(4):493-8. doi: 10.3748/wjg.v17.i4.493.

41.

Usefulness of manometry to select patients with anal fissure for controlled anal dilatation.

Santander C, Gisbert JP, Moreno-Otero R, McNicholl AG, Maté J.

Rev Esp Enferm Dig. 2010 Dec;102(12):691-7.

42.

Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment.

Trapero-Marugán M, Mendoza J, Moreno Monteagudo JA, Chaparro M, García-Buey L, González-Moreno L, Borque MJ, Moreno-Otero R.

J Clin Pharm Ther. 2011 Dec;36(6):695-703. doi: 10.1111/j.1365-2710.2010.01231.x. Epub 2010 Dec 22.

PMID:
21175705
43.

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.

Poynard T, Munteanu M, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Boparai N, Griffel L, Burroughs M, Brass C, Albrecht J.

J Hepatol. 2011 Feb;54(2):227-35. doi: 10.1016/j.jhep.2010.06.038. Epub 2010 Sep 15. Erratum in: J Hepatol. 2013 Oct;59(4):914.

PMID:
21056496
44.

Antioxidants for liver disease.

Moreno-Otero R, Trapero-Marugán M.

Aliment Pharmacol Ther. 2010 Nov;32(10):1292-3; author reply 1293-4. doi: 10.1111/j.1365-2036.2010.04441.x. No abstract available.

45.

Drug-induced postinfantile giant cell hepatitis.

Moreno-Otero R, Trapero-Marugán M, García-Buey L, García-Sancchez A.

Hepatology. 2010 Dec;52(6):2245-6. doi: 10.1002/hep.23830. Epub 2010 Oct 1. No abstract available.

PMID:
20890941
46.

Liver disease and erythropoietic protoporphyria: a concise review.

Casanova-González MJ, Trapero-Marugán M, Jones EA, Moreno-Otero R.

World J Gastroenterol. 2010 Sep 28;16(36):4526-31. Review.

47.

Prospective evaluation of a clinical guideline recommending early patients discharge in bleeding peptic ulcer.

Chaparro M, Barbero A, Martín L, Esteban C, Espinosa L, de la Morena F, Sánchez A, Martín I, Santander C, Moreno-Otero R, Gisbert JP.

J Gastroenterol Hepatol. 2010 Sep;25(9):1525-9. doi: 10.1111/j.1440-1746.2010.06374.x.

PMID:
20796150
48.

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.

Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, Rodriguez-Caravaca G, Bárcena R, Serra MA, Romero-Gómez M, Fernandez I, Garcia-Samaniego J, Fuente J, Solá R, Moreno-Otero R, Planas R; Group for the Assessment of Prevention of Cirrhosis Complications and Virological Response (APREVIR).

Am J Gastroenterol. 2010 Oct;105(10):2164-72; quiz 2173. doi: 10.1038/ajg.2010.294. Epub 2010 Aug 10. Erratum in: Am J Gastroenterol. 2010 Oct;105(10):2308.

PMID:
20700116
49.

The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors.

Figueroa-Vega N, Díaz A, Adrados M, Alvarez-Escolá C, Paniagua A, Aragonés J, Martín-Pérez E, Leskela S, Moreno-Otero R, González-Amaro R, Marazuela M.

Endocr Relat Cancer. 2010 Oct 5;17(4):897-908. doi: 10.1677/ERC-10-0020. Print 2010 Dec.

PMID:
20696814
50.

Corticosteroids modulate angiogenic soluble factors in ulcerative colitis patients.

Pousa ID, Algaba A, Linares PM, Sanz-Cameno P, Maté J, Moreno-Otero R, Bermejo F, Gisbert JP.

Dig Dis Sci. 2011 Mar;56(3):871-9. doi: 10.1007/s10620-010-1327-x. Epub 2010 Jul 15.

PMID:
20632101

Supplemental Content

Loading ...
Support Center